Key Takeaways EXEL Q2 results may benefit from Cabometyx sales growth and recent label expansions. The drug's FDA approval for pNET and epNET might have driven incremental Q2 revenues. Positive STELLAR-303 data on zanzalintinib adds pipeline momentum heading into earnings.Investors will focus on lead drug Cabometyx’ performance when Exelixis ((EXEL) reports second-quarter 2025 results on July 28. The Zacks Consensus Estimate for sales and earnings is pegged at $527 million and 63 cents per share, respecti ...